Abstract
Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.
| Original language | English |
|---|---|
| Pages (from-to) | 647-655 |
| Number of pages | 9 |
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 64 |
| Issue number | 4 |
| DOIs | |
| State | Published - Sep 2009 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Alkylating chemotherapy
- Brain tumor
- Glioblastoma
- Malignant glioma
- Temozolomide
- Tumor resistance
ASJC Scopus subject areas
- Oncology
- Toxicology
- Pharmacology
- Cancer Research
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Temozolomide in malignant gliomas: Current use and future targets'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver